Introduction of biopharmaceuticals in Europe : a cross-sectional study of early diffusion patterns and data availability

Tools

Veszelei, Ivar and Godman, Brian and Aaltonen, Katri and Selke, Gisbert W. and Garuolienė, Kristina and Cangini, Agnese and Kurdi, Amanj and Teixeira Rodrigues, António and Pontes, Caridad and Torre, Carla and Lunghi, Carlotta and Burton, Edel and Poplavska, Elita and Jónsdóttir, Freyja and Petrova, Guenka and Langer, Irene and Iaru, Irina and Odnoletkova, Irina and Slabý, Juraj and Gvozdanović, Katarina and Saastamoinen, Leena and Laius, Ott and Benkö, Ria and Žiogaitė, Silvija and McTaggart, Stuart and Mueller, Tanja and de Pando, Thais and Tesař, Tomáš and Mitkova, Zornitsa and Wettermark, Björn (2025) Introduction of biopharmaceuticals in Europe : a cross-sectional study of early diffusion patterns and data availability. BioDrugs, 39 (5). pp. 735-751. ISSN 1179-190X (https://doi.org/10.1007/s40259-025-00732-2)

[thumbnail of Veszelei-etal-BioDrugs-2025-Introduction-of-biopharmaceuticals-in-Europe]
Preview
 Text. Filename: Veszelei-etal-BioDrugs-2025-Introduction-of-biopharmaceuticals-in-Europe.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial 4.0 logo
Download (3MB)| Preview

Abstract

Background and Objectives: Biopharmaceuticals add value in the treatment of many diseases but different health systems in Europe face clinical and economic challenges with introducing them. Joint efforts across Europe are therefore essential to ensure their sustainable and equitable use. However, to date few cross-national comparative studies have assessed their introduction. This study aimed to assess the availability of health authority data and variation in the early diffusion of biopharmaceuticals across Europe. Methods: A cross-sectional study was undertaken to analyze the diffusion of 17 biopharmaceuticals, approved between 2015 and 2019, among European countries between 2015 and 2022. The study assessed data availability, diffusion rates measured as accumulated defined daily doses per 1000 inhabitants, as well as relative rankings between countries during the first 4 years following market authorization. Results: Twenty countries and two regions out of 31 European countries provided data on biopharmaceutical utilization for out-of-hospital care, 15 provided wholesaler data, and 14 provided hospital data. Certain countries and regions contributed data in multiple categories, while six did not provide any data. Diffusion rates were assessed for 17 countries and two regions, which showed appreciable variation, with secukinumab and erenumab being introduced in most countries and follitropin delta and tildrakizumab in the least number of countries. Germany, Austria, and Norway demonstrated the highest early diffusion rates, while Lithuania, Romania, and Latvia had the lowest. Conclusions: This study revealed a substantial variation between European countries and regions in the early diffusion of biopharmaceuticals and the availability of data to monitor their use. The reasons behind these patterns require further investigation to support European countries in optimizing the use of biopharmaceuticals to reach an equitable and cost-effective use of medicines across Europe.

ORCID iDs

Veszelei, Ivar, Godman, Brian, Aaltonen, Katri, Selke, Gisbert W., Garuolienė, Kristina, Cangini, Agnese, Kurdi, Amanj ORCID logoORCID: https://orcid.org/0000-0001-5036-1988, Teixeira Rodrigues, António, Pontes, Caridad, Torre, Carla, Lunghi, Carlotta, Burton, Edel, Poplavska, Elita, Jónsdóttir, Freyja, Petrova, Guenka, Langer, Irene, Iaru, Irina, Odnoletkova, Irina, Slabý, Juraj, Gvozdanović, Katarina, Saastamoinen, Leena, Laius, Ott, Benkö, Ria, Žiogaitė, Silvija, McTaggart, Stuart, Mueller, Tanja ORCID logoORCID: https://orcid.org/0000-0002-0418-4789, de Pando, Thais, Tesař, Tomáš, Mitkova, Zornitsa and Wettermark, Björn;
CORE (COnnecting REpositories)